Rituximab in pemphigus
- 31 December 2017
- journal article
- research article
- Published by Informa UK Limited in Immunotherapy
- Vol. 10 (1), 27-37
- https://doi.org/10.2217/imt-2017-0104
Abstract
Pemphigus is a severe autoimmune blistering diseasemediated by pathogenic anti-desmoglein antibodies leading to an inter keratinocyte disjunction. Rituximab is a monoclonal antibody that binds to the CD-20 antigen of B lymphocytes, which causes B-cell depletion and a subsequent reduction in pathogenic autoantibodies. Its therapeutic role in pemphigus has been progressively growing with increasing evidence of successful outcomes. Rituximab was initially off-labeled used as an alternative in patients with recalcitrant or relapsing pemphigus and in patients with contraindications to systemic corticosteroids. Recently, a large randomized clinical trial has shown that first-line use of rituximab combined with short-term prednisone regimen was both more effective and potentially safer than a standard regimen of high doses of corticosteroids in patients with moderate to severe pemphigus.Keywords
This publication has 94 references indexed in Scilit:
- Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroidsJournal of the American Academy of Dermatology, 2013
- Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interfaceJCI Insight, 2012
- Enrichment of total serum IgG4 in patients with pemphigusBritish Journal of Dermatology, 2012
- Long-Term Prognosis of Pemphigus in Korea: Retrospective Analysis of 199 PatientsDermatology, 2011
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus VulgarisDermatology Research and Practice, 2010
- Indications of Rituximab in autoimmune diseasesDrug Discovery Today: Therapeutic Strategies, 2009
- Pemphigus, Bullous Impetigo, and the Staphylococcal Scalded-Skin SyndromeNew England Journal of Medicine, 2006
- The Pathogenic Effect of IgG4 Autoantibodies in Endemic Pemphigus Foliaceus (Fogo Selvagem)New England Journal of Medicine, 1989
- Induction of Pemphigus in Neonatal Mice by Passive Transfer of IgG from Patients with the DiseaseNew England Journal of Medicine, 1982